Welcome to our dedicated page for Glaukos Corporation news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos Corporation stock.
Glaukos Corporation (NYSE: GKOS) is a prominent ophthalmic medical technology company specializing in breakthrough products and procedures aimed at transforming the treatment of glaucoma. As one of the leading causes of blindness globally, glaucoma demands innovative solutions, and Glaukos has pioneered micro-invasive glaucoma surgery (MIGS) to revolutionize traditional management paradigms.
The company's flagship product, the iStent Trabecular Micro-Bypass Stent, launched in the United States in 2012, is celebrated for being the smallest medical device ever approved by the FDA, measuring a mere 1.0 mm long and 0.33 mm wide. This device is designed to reduce intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma when used in conjunction with cataract surgery.
Building on the success of the iStent, Glaukos is developing a comprehensive and proprietary portfolio of injectable micro-scale therapies targeting the entire spectrum of glaucoma disease states and progression. The pipeline includes the iStent SA Trabecular Micro-Bypass System, a two-stent product with a different auto-injection inserter for standalone procedures.
In June 2015, Glaukos successfully completed its initial public offering, and its shares are now publicly traded on the New York Stock Exchange. The company continues to innovate and expand its product offerings, maintaining its position as a leader in the ophthalmic medical technology field.
- Recent achievements include the expansion of their product pipeline and the ongoing development of next-generation MIGS devices.
- Current projects focus on enhancing the efficacy and accessibility of glaucoma treatments worldwide.
- Partnerships with leading ophthalmic institutions and research organizations fuel Glaukos' mission to improve patient outcomes.
Glaukos Corporation remains committed to transforming glaucoma treatment through technological innovation and strategic growth.
Glaukos (NYSE: GKOS) reported strong financial results for Q2 2024, with record net sales of $95.7 million, up 19% year-over-year. The company's Glaucoma segment saw a 23% increase in net sales to $75.9 million, while Corneal Health net sales grew 7% to $19.8 million. Gross margin improved to 76%, with non-GAAP gross margin at 82%. Despite the revenue growth, Glaukos reported a net loss of $53.9 million, or ($1.06) per diluted share. The company raised its 2024 net sales guidance to $370-$376 million, up from the previous $357-$365 million range. Glaukos ended the quarter with approximately $266.4 million in cash and investments.
Glaukos (NYSE: GKOS), specializing in ophthalmic pharmaceuticals and medical technology, will release its second quarter 2024 financial results after market close on Wednesday, July 31, 2024. The announcement will be discussed by company management during a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET).
Access to the live webcast will be available on the company's investor relations website. Interested parties can join the conference call by dialing 888-210-2212 (U.S.) or 646-960-0390 (International) with the Conference ID 7935742. A replay will be available on Glaukos' website after the call.
Glaukos (NYSE: GKOS) has entered into privately negotiated exchange agreements with certain holders of its 2.75% Convertible Senior Notes due 2027.
The company plans to repurchase $230 million in principal amount of these notes. The consideration will comprise shares of Glaukos' common stock and cash for fractional shares and accrued interest.
The exchanges are expected to close around June 25, 2024, and the shares issued will not be registered under the Securities Act of 1933.
This action is not an offer to sell or a solicitation to buy these securities in any jurisdiction where such actions would be illegal.
Glaukos (NYSE: GKOS) has announced its participation in two upcoming investor conferences: the William Blair 44th Annual Growth Stock Conference on June 5, 2024, at 1:40 p.m. ET in Chicago, and the Truist MedTech Conference on June 18, 2024, at 12:45 p.m. ET in Boston. Glaukos specializes in therapies for glaucoma, corneal disorders, and retinal diseases. Live and archived webcasts of these events will be available on the Glaukos website.
Glaukos (NYSE: GKOS) reported strong financial results for the first quarter of 2024, with record net sales of $85.6 million, marking a 16% increase year-over-year. The company raised its 2024 net sales guidance to $357 to $365 million. Glaukos continues to focus on developing innovative technologies to enhance patient care in ophthalmology.
FAQ
What is the current stock price of Glaukos Corporation (GKOS)?
What is the market cap of Glaukos Corporation (GKOS)?
What is Glaukos Corporation?
What is the iStent Trabecular Micro-Bypass Stent?
When did Glaukos go public?
What is MIGS?
What is the iStent SA?
What recent achievements has Glaukos made?
What is the significance of Glaukos' products?
Who are Glaukos' partners?
What is Glaukos' mission?
How does Glaukos continue to innovate?
